Citation Impact
Citing Papers
What Do We Really Know About Mindfulness-Based Stress Reduction?
2002 Standout
Midazolam: A review of therapeutic uses and toxicity
1997
Effects of prolactin on central dopaminergic neurons
1982
Adrenergic α2C-Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice
1998 StandoutNobel
5-Hydroxytryptamine pathways in anxiety and its treatment
1995
Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography
1993
Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone
1998 StandoutNobel
DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS
2002
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
1995
Molecular, pharmacological and functional diversity of 5-HT receptors
2002 Standout
How to perform a meta-analysis with R: a practical tutorial
2019 Standout
Chlorpromazine versus placebo for schizophrenia
2007
Quality-of-Life Impairment in Depressive and Anxiety Disorders
2005 Standout
Twelve-Month Use of Mental Health Services in the United States
2005 Standout
Presence of thallium in the environment: sources of contaminations, distribution and monitoring methods
2016 Standout
Dopamine transporter function differences between male and female CD-1 mice
2005
The empirical status of cognitive-behavioral therapy: A review of meta-analyses
2005 Standout
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation
1997 Standout
The cortical serotonin2Areceptor and the pathology of schizophrenia: a likely accomplice
2003
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
2012
Posttraumatic Stress Disorder: Diagnosis and Epidemiology, Comorbidity and Social Consequences, Biology and Treatment
2001
Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database
2012
Modulation of Brain Dopamine Transmission by Sex Steroids
1994
Phencyclidine in the Social Interaction Test: An Animal Model of Schizophrenia with Face and Predictive Validity
1999
Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: Antagonism by atypical antipsychotic drugs
1994
Adolescent suicide and suicidal behavior
2006 Standout
What Is a “Mood Stabilizer”? An Evidence-Based Response
2004
Clinician-administered PTSD scale: A review of the first ten years of research
2001 Standout
Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings
2009 Standout
Banana (Musa spp) from peel to pulp: Ethnopharmacology, source of bioactive compounds and its relevance for human health
2014 Standout
??-1 Receptor Ligands
2004
A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder
1994
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
1999 Standout
Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia
2000 Standout
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
1996
Serotonergic drugs in the treatment of depressive and anxiety disorders
2000
A review of central 5-HT receptors and their function
1999 Standout
Consensus Statement on Management of Intersex Disorders
2006 Standout
Haloperidol versus placebo for schizophrenia
2001
Adverse Effects of Atypical Antipsychotics
2007
A critical review of psychological treatments of posttraumatic stress disorder in refugees
2010 Standout
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
1999 Standout
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
1999
Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress Disorder
2000
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
2008
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
Estrogen Actions in the Central Nervous System1
1999 Standout
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
2003
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
2003 Standout
Comparison of haloperidol and midazolam in restless management of patients referred to the Emergency Department: A double-blinded, randomized clinical trial
2015
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
2007 Standout
In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH 23390
1988 StandoutNobel
Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival
2007 Standout
Industry sponsorship and research outcome
2012 Standout
Effects of estrogen on the basal ganglia
1986
Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications
2012
Elevation of Serum Corticosterone Concentrations in Rats by Pergolide and Other Dopamine Agonists
1981
Imputation methods for missing outcome data in meta-analysis of clinical trials
2008
Chlorpromazine versus placebo for schizophrenia
2014
Risperidone versus typical antipsychotic medication for schizophrenia
2003
Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement
2009 Standout
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration
2014 Standout
Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis
1997
Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice
1998 Standout
Chronic treatment withl-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding
1986
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis
1998
Anticonflict effects of low doses of the dopamine agonist apomorphine in the rat
1986 StandoutNobel
How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study
2003 Standout
National Service Framework for Mental Health
2000 Standout
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats
1985
Risperidone
1994
The Neuropsychology of Anxiety
2003 Standout
Haloperidol versus placebo for schizophrenia
2013
Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment
2006
Interactions of Persistent Environmental Organohalogens With the Thyroid Hormone System: Mechanisms and Possible Consequences for Animal and Human Health
1998
Risperidone versus placebo for schizophrenia
2016
A review of clinical efficacy of 5-HT 1A agonists in anxiety and depression
1993
Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region
1996 StandoutScience
Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses
2001 Standout
Risperidone Dose-Dependently Increases Extracellular Concentrations of Serotonin in the Rat Frontal Cortex: Role of α2-Adrenoceptor Antagonism
1997
Industry sponsorship and research outcome
2017 Standout
Prescribed drugs containing nitrogen heterocycles: an overview
2020 Standout
Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials
1997
Hallucinogens
2004 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of B.I. Diamond being referenced
Risperidone: clinical safety and efficacy in schizophrenia.
1992
A comparative study of alpidem, a nonbenzodiazepine, and lorazepam in patients with nonpsychotic anxiety.
1991
A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder
1995
Modulation of dopamine receptor sensitivity by estrogen.
1980
Does sigma receptor antagonism predict clinical antipsychotic efficacy?
1991
The use of midazolam in acutely agitated psychiatric patients.
1990
The pharmacological evaluation of pergolide mesylate as a potential anti-Parkinson agent
1980
Sigma receptor antagonism and antipsychotic actions in schizophrenic patients
1990
Clozapine withdrawal rebound psychosis.
1988
Hypophysectomy induced hypersensitivity to dopamine: Antagonism by estrogen
1981
Efficacy and safety of a putative anxiolytic agent: ipsapirone.
1990
Risperidone in the treatment of acute exacerbation of chronic schizophrenia
1991
Relationship between creatine phosphokinase, psychotic symptoms and novel antipsychotic drugs
1995